Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02294305
Recruitment Status : Unknown
Verified August 2016 by The Medical Research Network.
Recruitment status was:  Active, not recruiting
First Posted : November 19, 2014
Last Update Posted : August 24, 2016
Sponsor:
Information provided by (Responsible Party):
The Medical Research Network

Brief Summary:
This placebo-controlled study is designed to determine the efficacy, safety, and tolerability of vortioxetine in the treatment of adults with Major Depressive Disorder (MDD) that is comorbid with Social Anxiety Disorder (SAD). Half of the subjects will be randomized to receive vortioxetine and the other half will receive placebo.

Condition or disease Intervention/treatment Phase
Social Anxiety Disorder Major Depressive Disorder Drug: Vortioxetine Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : December 2014
Estimated Primary Completion Date : November 2016
Estimated Study Completion Date : November 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Arm Intervention/treatment
Experimental: Vortioxetine
Vortioxetine 10 to 20 mg PO QD for 12 weeks.
Drug: Vortioxetine
Other Name: Brintellix

Placebo Comparator: Placebo
Placebo PO QD for 12 weeks.
Drug: Placebo



Primary Outcome Measures :
  1. Clinical Global Impression of Improvement (CGI-I) Responder Rate [ Time Frame: 12 weeks ]
    CGI-I score of 2 (much improved) or 1 (very much improved) based on overall subject state, combining improvement in MDD and SAD features, at Visit 9/Early Termination


Secondary Outcome Measures :
  1. Change in total Montgomery Asberg Depression Rating Scale (MADRS) score [ Time Frame: Baseline and 12 Weeks ]
  2. Change in total Liebowitz Social Anxiety Scale (LSAS) score [ Time Frame: Baseline and 12 Weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female adults between 18 and 70 years of age (inclusive).
  2. Subjects must give written informed consent prior to any study procedures
  3. Diagnosis of Major Depressive Disorder (MDD), single episode (296.2) or recurrent (296.3), according to Diagnostic and Statistical Manual of Mental Disorders, version 5 (DSM-5) criteria, as determined by psychiatric evaluation with the investigator and confirmed by the Mini-International Neuropsychiatric Interview (MINI).
  4. Duration of current Major Depressive Episode must be at least 4 weeks.
  5. Diagnosis of Social Anxiety Disorder (SAD) (300.23 Social Phobia) according to DSM-5 criteria, as determined by psychiatric evaluation with the Investigator and confirmed by the MINI.
  6. Duration of current SAD must be at least 6 months, and SAD should be observable in subjects' lives when they are not suffering from MDD, if such periods have occurred.
  7. Subjects must have a minimum total score of 60 on the Liebowitz Social Anxiety Scale (LSAS) at both Screening and Baseline visits.
  8. Subjects must have a minimum total Montgomery Asberg Depression Rating Scale (MADRS) score of 20 at both Screening and Baseline visits.
  9. Subjects must have a Clinical Global Inventory (CGI) Severity score of 4 or greater at both Screening and Baseline visits, where the CGI is based on a composite of MDD and SAD.
  10. Male and female subjects of childbearing potential must commit to an effective form of contraception for the duration of the trial (Screening/Visit 1 through Follow-Up/Visit 10). Effective forms of contraception include: condoms with spermicide, diaphragm with spermicide, hormonal contraceptive agents (oral, transdermal, or injectable), or implantable contraceptive devices. True abstinence will also be considered an effective form of contraception.

Exclusion Criteria:

  1. Subjects with any lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder, Obsessive Compulsive Disorder, eating disorders, or body dysmorphic disorder. Subjects with comorbid Generalized Anxiety Disorder, dysthymia, or specific phobias can be included in the study provided that MDD and SAD are considered to be the primary clinical conditions in terms of need for treatment.
  2. Subjects with substance abuse, panic disorder, or Post-Traumatic Stress Disorder, in the past 6 months before screening.
  3. Subjects who started psychotherapy for SAD or MDD or had electroconvulsive therapy (ECT) in the past 6 months before screening. Subjects who have been receiving psychotherapy or Cognitive Behavioral Therapy for more than 24 weeks prior to the Baseline visit are eligible provided that the therapy continues at the same frequency for the duration of the trial.
  4. Subjects who are currently pregnant or lactating, or who are of childbearing potential and not able and willing to practice an effective method of contraception (as outlined in Inclusion criterion #10) for the duration of the trial (Screening/Visit 1 through Follow-Up/Visit 10.
  5. Subjects who, in the opinion of the investigator, are at a clinically significant risk for suicide. This would include prominent suicidal ideation or suicidal behavior in the past 6 months before screening.
  6. Systolic blood pressure ≥165 and/or diastolic blood pressure ≥95, as measured at Screening and Baseline visits.
  7. Positive Urine Drug Screen at the Screening visit, unless due to prescribed medication.
  8. Any current unstable and/or clinically significant medical condition, based on history or as evidenced in screening laboratory or electrocardiogram (ECG) assessments.
  9. Subjects with a history or complication of cancer or malignant tumor not in remission for at least 5 years. Basal cell skin cancers are not exclusionary.
  10. Subjects receiving fluoxetine within 28 days of the Baseline visit.
  11. Subjects receiving Monoamine oxidase inhibitors (MAOIs) within 14 days of the Baseline visit.
  12. Subjects receiving any other psychotropic medication (including selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and benzodiazepines) within 14 days of the Baseline visit. Zolpidem (Ambien) PRN is allowed for insomnia if not taken more than 3 times per week for the duration of the trial.
  13. Treatment refractory SAD: subjects who have a history of two or more failed treatment trials with an FDA-approved SAD treatment, each given for at least 6 weeks, during which the subject received an adequate dosage
  14. Treatment refractory MDD: subjects who have a history of two or more failed treatment trials with an FDA-approved MDD treatment in the current episode

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02294305


Locations
Layout table for location information
United States, New York
The Medical Research Network, LLC
New York, New York, United States, 10128
Sponsors and Collaborators
The Medical Research Network
Investigators
Layout table for investigator information
Principal Investigator: Michael R Liebowitz, M.D. The Medical Research Network, LLC

Layout table for additonal information
Responsible Party: The Medical Research Network
ClinicalTrials.gov Identifier: NCT02294305    
Other Study ID Numbers: TAK-S001560
First Posted: November 19, 2014    Key Record Dates
Last Update Posted: August 24, 2016
Last Verified: August 2016
Keywords provided by The Medical Research Network:
Depression
Social Anxiety
Social Phobia
Major Depression
Vortioxetine
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Anxiety Disorders
Depressive Disorder
Depression
Depressive Disorder, Major
Phobia, Social
Pathologic Processes
Mental Disorders
Mood Disorders
Behavioral Symptoms
Phobic Disorders
Vortioxetine
Antidepressive Agents
Psychotropic Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin 5-HT3 Receptor Antagonists
Serotonin Antagonists